Jarvik Heart Announces Full FDA Approval of the Jarvik 2000 Destination Therapy Trial

Jarvik Heart announced full FDA approval of its Pivotal Trial for evaluation of the Jarvik 2000 heart for destination therapy named RELIVE.
Qmed